Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mechanisms of Action: Physiological Effects

Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates

Bartolome Moya, Isabel M. Barcelo, Sachin Bhagwat, Mahesh Patel, German Bou, Krisztina M. Papp-Wallace, Robert A. Bonomo, Antonio Oliver
Bartolome Moya
aServicio de Microbiología and Unidad de Investigación, Hospital Son Espases, Instituto de Investigación Sanitaria de Palma (IdISPa), Palma de Mallorca, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Isabel M. Barcelo
aServicio de Microbiología and Unidad de Investigación, Hospital Son Espases, Instituto de Investigación Sanitaria de Palma (IdISPa), Palma de Mallorca, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sachin Bhagwat
bWockhardt Research Centre, Aurangabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mahesh Patel
bWockhardt Research Centre, Aurangabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
German Bou
cServicio de Microbiología, Complejo Hospitalario Universitario A Coruña, A Coruña, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Krisztina M. Papp-Wallace
dResearch Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA
eDepartments of Medicine and Biochemistry, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert A. Bonomo
dResearch Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA
eDepartments of Medicine and Biochemistry, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
fDepartments of Pharmacology and Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonio Oliver
aServicio de Microbiología and Unidad de Investigación, Hospital Son Espases, Instituto de Investigación Sanitaria de Palma (IdISPa), Palma de Mallorca, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Antonio Oliver
DOI: 10.1128/AAC.01238-17
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Multidrug-resistant Acinetobacter baumannii has rapidly spread worldwide, resulting in a serious threat to hospitalized patients. Zidebactam and WCK 5153 are novel non-β-lactam bicyclo-acyl hydrazide β-lactam enhancer antibiotics being developed to target multidrug-resistant A. baumannii. The objectives of this work were to determine the 50% inhibitory concentrations (IC50s) for penicillin-binding proteins (PBP), the OXA-23 inhibition profiles, and the antimicrobial activities of zidebactam and WCK 5153, alone and in combination with β-lactams, against multidrug-resistant A. baumannii. MICs and time-kill kinetics were determined for an A. baumannii clinical strain producing the carbapenemase OXA-23 and belonging to the widespread European clone II of sequence type 2 (ST2). Inhibition of the purified OXA-23 enzyme by zidebactam, WCK 5153, and comparators was assessed. All of the compounds tested displayed apparent Ki values of >100 μM, indicating poor OXA-23 β-lactamase inhibition. The IC50s of zidebactam, WCK 5153, cefepime, ceftazidime, meropenem, and sulbactam (range of concentrations tested, 0.02 to 2 μg/ml) for PBP were also determined. Zidebactam and WCK 5153 demonstrated specific high-affinity binding to PBP2 of A. baumannii (0.01 μg/ml for both of the compounds). The MICs of zidebactam and WCK 5153 were >1,024 μg/ml for wild-type and multidrug-resistant Acinetobacter strains. Importantly, combinations of cefepime with 8 μg/ml of zidebactam or WCK 5153 and sulbactam with 8 μg/ml of zidebactam or WCK 5153 led to 4- and 8-fold reductions of the MICs, respectively, and showed enhanced killing. Notably, several of the combinations resulted in full bacterial eradication at 24 h. We conclude that zidebactam and WCK 5153 are PBP2 inhibitors that show a potent β-lactam enhancer effect against A. baumannii, including a multidrug-resistant OXA-23-producing ST2 international clone.

INTRODUCTION

Multidrug-resistant (MDR) Acinetobacter baumannii is one of the most challenging Gram-negative pathogens and is difficult to treat due to its extraordinary ability to acquire resistance determinants affecting all the antibacterial classes (1, 2). The percentage of multidrug-resistant A. baumannii clinical isolates is over 70% worldwide (3–6). Moreover, MDR A. baumannii is associated with 30-day mortality rates well above 60% when an inappropriate empirical therapy and/or dosing regimen is provided (7). As a result of the worldwide spread of MDR A. baumannii and the increased prevalence of carbapenem-resistant A. baumannii (CRAB), no appropriate therapy is available to successfully treat infections caused by this pathogen (8–10). A. baumannii is intrinsically resistant to various antibiotics owing to the low permeability of its outer membrane (11, 12). Moreover, the diminished or truncated expression of outer membrane porins further decreases carbapenem permeation (13, 14).

The Acinetobacter baumannii carbapenem resistance repertoire can be further extended by the acquisition of an oxacillinase (10, 15, 16) and/or a class B carbapenemase enzyme (17, 18). blaOXA-23 is the most widely prevalent A. baumannii-associated carbapenem-hydrolyzing β-lactamase.

Sulbactam remained a treatment option until the widespread emergence of OXA-23 in A. baumannii took place (19, 20). Tigecycline showed initial promise for the treatment of A. baumannii infections; however, its limited tolerability in critically ill patients and pharmacokinetic/pharmacodynamic (PK/PD) limitations often lead to suboptimal clinical outcomes (21, 22). Certain old revived drugs, like fosfomycin, temocillin, rifampin, minocycline, or colistin, have been deployed against MDR A. baumannii with variable success rates, besides the limitations of narrow indications and ill-defined PK/PD (9, 23–29), and β-lactamase inhibitors such as clavulanic acid (CLA), tazobactam (TAZ), avibactam (AVI), relebactam (REL), and RG6080 have not been able to fully overcome the class D OXA carbapenemase-associated resistance in A. baumannii (30–35).

In view of the excellent safety profiles of cephalosporins, a cephalosporin-based combination active against MDR A. baumannii would provide an attractive therapeutic option. The new bicyclo-acyl hydrazides (BCH) zidebactam (ZID; previously WCK 5107) and WCK 5153 are enhanced β-lactam antibiotics displaying a high-affinity for penicillin binding protein 2 (PBP2) of Gram-negative bacteria and overcoming diverse β-lactam resistance mechanisms, such as metallo-β-lactamases (MBL) in Pseudomonas aeruginosa. Zidebactam in combination with cefepime (WCK 5222) is being developed as a treatment for infections caused by MDR and extensively drug-resistant bacteria and is slated to enter phase 3 clinical trials (36–38).

The objectives of this work were to determine the PBP-binding affinity, the OXA-23 inhibition profiles, and the antimicrobial activities of zidebactam and WCK 5153 in combination with cefepime (WCK 5222) and sulbactam against MDR A. baumannii.

RESULTS AND DISCUSSION

Table 1 summarizes the MICs of zidebactam, WCK 5153, the comparators, and their combinations with cefepime and sulbactam against the wild-type strain A. baumannii ATCC 19606 and an A. baumannii OXA-23-producing sequence type 2 (ST2) strain. The MICs of imipenem, cefepime, and sulbactam for the OXA-23-producing isolate were 32, 64, and 16 μg/ml, respectively. The addition of zidebactam or WCK 5153 (8 μg/ml) lowered the MICs of cefepime and sulbactam (Table 1), suggesting a notable enhancer effect.

View this table:
  • View inline
  • View popup
TABLE 1

Susceptibility to β-lactams and WCK bicyclo-acyl hydrazides in the studied strainsa

As previously shown in P. aeruginosa (38), zidebactam and WCK 5153 demonstrated a potent affinity for A. baumannii PBP2 with a 50% inhibitory concentration (IC50) of 0.01 μg/ml, which was 7 to 8 times lower than that of imipenem and comparable to that of meropenem, both of which are well-documented potent PBP2-binding agents (Table 2; Fig. 1). Such high-affinity binding to A. baumannii PBP2 has not been previously reported for other diazabicyclooctanes (DBOs), such as relebactam, avibactam, and RG6080 (nacubactam). Similar to a recent report (39), our study also shows that cefepime and sulbactam bind to multiple A. baumannii PBPs, showing the highest affinities for PBP3 (IC50s, 0.08 and 0.64 μg/ml, respectively), as well as inhibit PBP1a and PBP1b, respectively (Table 2).

View this table:
  • View inline
  • View popup
TABLE 2

IC50s of cefepime, ceftazidime, imipenem, meropenem, sulbactam, zidebactam, and WCK 5153 for A. baumannii ATCC 19606 PBPs

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

Illustrative example of SDS-polyacrylamide gels. Twenty micrograms of an A. baumannii PBP-containing membrane preparation was incubated in the presence of increasing concentrations of cefepime (FEP), imipenem (IMP), ceftazidime (CAZ), meropenem (MEM), sulbactam (SUL), and zidebactam (ZID) and afterwards was labeled with 25 μM Bocillin FL. The range of concentrations tested was 0.0156 to 2 μg/ml.

PBP-binding determinations reported in the literature suggest that most of the drugs tested have a higher affinity for A. baumannii PBP2 than for the orthologues in other species (40, 41), possibly because the number/ratio of PBP2 molecules per cell is lower in A. baumannii than other Gram-negative bacteria. Such a limited availability of PBP2 molecules lends a high functional criticality, thus making PBP2 an even more valuable target (42). Microscopy-based observations confirmed that significantly sub-MICs of zidebactam or WCK 5153 (<1/128× MIC) induced spheroplast formation; furthermore, the combination of either drug with cefepime resulted in the formation of larger spheroplasts (38, 39).

OXA-23 inhibition studies with zidebactam, WCK 5153, and the comparator compounds revealed apparent Ki (Ki app) values of >100 μM for all compounds tested, consistent with previously reported data for avibactam and relebactam (1, 30).

The killing kinetics of the A. baumannii OXA-23 ST2 isolate showed that zidebactam and WCK 5153 alone did not elicit a bactericidal effect owing to their sole PBP2-binding feature. Nevertheless, combinations of 8 μg/ml zidebactam or WCK 5153 with 8 μg/ml of cefepime (0.125× MIC) displayed an initial 1.1- to 1.5-log10 kill for the first 8 h, followed by subsequent regrowth at 24 h (Fig. 2. On the other hand, higher concentration of cefepime (16 μg/ml, 0.25× MIC) in combination with 8 μg/ml of zidebactam or WCK 5153 provided sustained bactericidal activity of >3 log10, reaching complete eradication at 24 h. This enhanced bactericidal effect mediated through spheroplast formation was also confirmed through microscopy-based live-dead staining, in which a higher proportion of dead cells was observed (Fig. 3).

FIG 2
  • Open in new tab
  • Download powerpoint
FIG 2

Results of the killing curves measured in terms of the reduction in the number of viable CFU per milliliter over time of the A. baumannii ST2 OXA-23-producing isolate (an extensively drug-resistant OXA-23-producing A. baumannii ST2 international clone) by combinations of cefepime and sulbactam with zidebactam and WCK 5153. The concentrations of the drugs tested alone were 16 μg/ml for cefepime (FEP; 0.25× MIC), 0.5 μg/ml for tigecycline (TGC; 0.5× MIC), 16 μg/ml for imipenem (IPM; 0.5× MIC), 16 μg/ml for sulbactam (SUL; 1× MIC), and 8 μg/ml for zidebactam (ZID) and WCK 5153 (<0.003× MIC). For the combinations, the concentrations used were 8 μg/ml for zidebactam and WCK 5153 and 4, 8, and 16 μg/ml for the partner β-lactams cefepime and sulbactam. The mean values for three experiments ± standard deviations are shown. Dashed lines represent the limits of detection.

FIG 3
  • Open in new tab
  • Download powerpoint
FIG 3

LIVE/DEAD staining performed on A. baumannii MDR ST2 expressing OXA-23 (initial inoculum, 107 CFU/ml). The morphological changes observed after 3 h of exposure after inoculation in cation-adjusted-MHB (A), 8 μg/ml cefepime (B), 16 μg/ml cefepime (C), 8 μg/ml zidebactam (D), 8 μg/ml cefepime plus 8 μg/ml zidebactam (E), 16 μg/ml cefepime plus 8 μg/ml zidebactam (F), 8 μg/ml WCK 5153 (G), 8 μg/ml cefepime plus 8 μg/ml WCK 5153 (H), or 16 μg/ml cefepime plus 8 μg/ml WCK 5153 (I) are shown. The cefepime MIC was 64 μg/ml, the zidebactam MIC was ≥1,024 μg/ml, and the WCK 5153 MIC was ≥1,024 μg/ml. Bars, 10 μm.

Moreover, sulbactam at concentrations as low as 1/4 MIC (4 μg/ml) in combination with 8 μg/ml of either zidebactam or WCK 5153 elicited a faster response, resulting in a ≥3-log10 kill within 4 h which persisted until 24 h.

Concluding remarks.Combinations of zidebactam and WCK 5153 with PBP3-binding β-lactams exhibited synergistic killing of MDR A. baumannii, signifying the pivotal role of complementary PBP binding (43). Such combinations achieved pronounced bactericidal activity, even in the absence of OXA-23 carbapenemase inhibition, thus indicating the vulnerability of the spheroplasts induced by zidebactam to PBP3-binding agents, which otherwise are labile to the β-lactamases expressed by A. baumannii isolates.

Unlike the restoration of antibacterial activity reported for β-lactam and β-lactamase inhibitor combinations, zidebactam and WCK 5153 impart to PBP3-binding β-lactams rapid and consistent bactericidal effects, resulting in a pharmacodynamic action mimicking that of carbapenems, the most effective β-lactam class. Moreover, because zidebactam and WCK 5153 are non-β-lactams, they are not affected by classical β-lactam resistance mechanisms (34, 37, 38). The outcomes of this study demonstrate for the first time the principle of the activity of β-lactam enhancers against A. baumannii (37), which trigger bactericidal activity through complementary PBP binding, besides eluding the plethora of resistance mechanisms encountered in multidrug-resistant A. baumannii.

In vivo studies involving a neutropenic mouse lung infection undertaken with the cefepime-zidebactam combination have further demonstrated the in vivo relevance of the enhancer mechanism against MDR A. baumannii (44). Therefore, our results encourage further evaluations, including in vivo and clinical studies, of the efficacy of the β-lactam–zidebactam or β-lactam–WCK 5153 combination for the treatment of infections caused by MDR A. baumannii. Our study provides insights into the β-lactam enhancer-based approach as an alternative to β-lactamase inhibition in overcoming multiple mechanisms of resistance in A. baumannii.

MATERIALS AND METHODS

Susceptibility testing.The MICs of zidebactam, WCK 5153, cefepime, sulbactam, imipenem, and tigecycline were determined by the standard Clinical and Laboratory Standards Institute (CLSI) broth microdilution method for the wild-type A. baumannii ATCC 19606 strain and for the class D oxacillinase (OXA-23)-producing A. baumannii MDR ST2 strain belonging to European clone II (45). For determination of the MICs of drug combinations, zidebactam and WCK 5153 were used at a fixed concentration of 8 μg/ml.

Cloning of blaOXA-23.The blaOXA-23 gene and its upstream ISAba1 were amplified from A. baumannii strain AB0057 and cloned into a modified pWH1266 vector (a vector that replicates in A. baumannii) in which ampicillin resistance was eliminated (ΔblaTEM-1) by inverse PCR (46). blaOXA-23 without the leader peptide sequence was amplified from pWH1266-blaOXA-23 and cloned into the pET28a(+) vector downstream of the 6× His tag and electroporated into Escherichia coli DH10B. The sequences of the resulting constructs were verified. E. coli BL21(DE3) cells were used for protein expression and purification.

Purification and inhibition of OXA-23. E. coli BL21(DE3) containing pET28(+)blaOXA-23 was grown in Super Optimal broth containing 50 μg/ml kanamycin at 37°C with shaking to achieve an optical density at 600 nm (OD600) of 0.8 and induced with 0.2 mM isopropyl-β-d-1-thiogalactopyranoside for 3 h. The cells were centrifuged and frozen at −20°C. Cells were lysed using a QIAexpress nickel-nitrilotriacetic acid (Ni-NTA) fast-start kit per the manufacturer's protocol (Qiagen Inc.). To remove the His tag, the eluted protein was incubated with thrombin overnight at 4°C. The cleaved protein was separated from the His-tagged peptides by size exclusion chromatography (SEC) using a HiLoad 16/60 Superdex 75 column. The apparent Ki (Kiapp) values of zidebactam, WCK 5153, avibactam, and relebactam for OXA-23 were determined as previously described (38).

PBP-binding assays.The PBP-binding affinities for zidebactam, WCK 5153, and the comparator β-lactams (cefepime, sulbactam, ceftazidime, and meropenem) were determined by using membrane preparations from the reference strain A. baumannii ATCC 19606 following previously described protocols (47).

Briefly, 400-ml late-log-phase (OD600 = 1) cultures of A. baumannii ATCC 19606 were collected by centrifugation, washed, and resuspended in 20 mM KH2PO4 with 140 mM NaCl, pH 7.5 (buffer A). Cells were sonicated and centrifuged at 4,000 × g for 20 min. Bacterial membranes were collected by ultracentrifugation. Twenty micrograms of the A. baumannii PBP-containing membrane preparation was incubated for 30 min at 35°C in the presence of increasing concentrations of zidebactam, WCK 5153, and the comparator β-lactams (range of concentrations tested, 0.0156 to 2 μg/ml). Membrane preparations were incubated for an additional 30 min with 25 μM Bocillin FL (48). PBPs were separated by 10% SDS-polyacrylamide gel electrophoresis (Bio-Rad Laboratories, Hercules, CA) and visualized using a Typhoon FLA 9500 biomolecular imager (GE Healthcare Bio-Sciences AB, Björkgatan, Uppsala, Sweden) (excitation at 488 nm and emission at 530 nm). The IC50s for the different PBPs were determined from three independent experiments.

In addition, the morphological changes induced by cefepime and/or zidebactam or WCK5153 on the A. baumannii MDR ST2 isolate (expressing OXA-23) were visualized via live-dead staining using a LIVE/DEAD BacLight bacterial viability kit (Molecular Probes, Invitrogen, Carlsbad, CA) according to the manufacturer's instructions and an AxioScope A1 fluorescence microscope (Carl Zeiss MicroImaging, GmbH).

Time-kill assays.Overnight Mueller-Hinton broth (MHB) cultures of the OXA-23-producing A. baumannii MDR ST2 strain were diluted (1/100) in fresh medium and incubated (37°C, 180 rpm) to an OD600 of 0.2 (mid-log-phase growth). Kill kinetics were initiated by inoculating 100 μl of mid-log-phase culture onto plates with 100 μl of MHB (initial inoculum, ∼106 CFU/ml) containing zidebactam or WCK 5153 at a final concentration of 8 μg/ of (MIC > 1,024 μg/ml) alone and in combination with 8 and 16 μg/ml of cefepime (0.125× and 0.25× cefepime MIC, respectively) or 4 μg/ml of sulbactam (0.25× MIC). Cefepime and sulbactam (both at 16 μg/ml), imipenem at 16 μg/ml, and tigecycline at 0.5 μg/ml were used alone as comparators. Cultures were then enumerated by plating serial dilutions on Mueller-Hinton agar at 1, 2, 4, 6, 8, and 24 h. All experiments were performed in triplicate.

ACKNOWLEDGMENTS

We thank Javier Piérola for his technical assistance with the fluorescence microscopy.

We thank Susan D. Rudin and Christopher R. Bethel for the cloning of blaOXA-23 and for the OXA-23 expression, purification, and kinetic experiments, respectively.

This work was supported by Wockhardt Bio AG, Switzerland, and by the Ministerio de Economía y Competitividad of Spain, Instituto de Salud Carlos III, cofinanced by the European Regional Development Fund (ERDF; A Way To Achieve Europe), through the Spanish Network for Research in Infectious Diseases (RD12/0015 and RD16/0016). The research reported in this publication was also supported in part by funds and/or facilities provided by the Cleveland Department of Veterans Affairs to K.M.P.-W. and R.A.B., Veterans Affairs Merit Review Program award 1I01BX002872 to K.M.P.-W., and Veterans Affairs Merit Review Program award 1I01BX001974 to R.A.B. from the U.S. Department of Veterans Affairs Biomedical Laboratory Research and Development Service and by the Geriatric Research Education and Clinical Center VISN 10 to R.A.B. R.A.B. is also supported by the Harrington Foundation and the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award numbers R21AI114508, R01AI100560, R01AI063517, and R01AI072219.

The contents do not represent the views of the U.S. Department of Veterans Affairs or the U.S. Government. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

B.M. and A.O. have received funds for research from Wockhardt Bio AG, Switzerland. M.P. is an employee and director of drug discovery research of Wockhardt Ltd., Wockhardt Research Centre. S.B. is an employee and shareholder of Wockhardt Ltd., Wockhardt Research Centre. All other authors have no conflict of interest to declare.

FOOTNOTES

    • Received 15 June 2017.
    • Returned for modification 9 July 2017.
    • Accepted 22 August 2017.
    • Accepted manuscript posted online 28 August 2017.
  • Copyright © 2017 American Society for Microbiology.

All Rights Reserved .

REFERENCES

  1. 1.↵
    1. Roca I,
    2. Espinal P,
    3. Vila-Farres X,
    4. Vila J
    . 2012. The Acinetobacter baumannii oxymoron: commensal hospital dweller turned pan-drug-resistant menace. Front Microbiol3:148. doi:10.3389/fmicb.2012.00148.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Dijkshoorn L,
    2. Nemec A,
    3. Seifert H
    . 2007. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol5:939–951. doi:10.1038/nrmicro1789.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Katsaragakis S,
    2. Markogiannakis H,
    3. Toutouzas KG,
    4. Drimousis P,
    5. Larentzakis A,
    6. Theodoraki EM,
    7. Theodorou D
    . 2008. Acinetobacter baumannii infections in a surgical intensive care unit: predictors of multi-drug resistance. World J Surg32:1194–1202. doi:10.1007/s00268-008-9571-3.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Consales G,
    2. Gramigni E,
    3. Zamidei L,
    4. Bettocchi D,
    5. De Gaudio AR
    . 2011. A multidrug-resistant Acinetobacter baumannii outbreak in intensive care unit: antimicrobial and organizational strategies. J Crit Care26:453–459. doi:10.1016/j.jcrc.2010.12.016.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. De Francesco MA,
    2. Ravizzola G,
    3. Peroni L,
    4. Bonfanti C,
    5. Manca N
    . 2013. Prevalence of multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa in an Italian hospital. J Infect Public Health6:179–185. doi:10.1016/j.jiph.2012.11.006.
    OpenUrlCrossRef
  6. 6.↵
    1. Hsueh PR,
    2. Teng LJ,
    3. Chen CY,
    4. Chen WH,
    5. Yu CJ,
    6. Ho SW,
    7. Luh KT
    . 2002. Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan. Emerg Infect Dis8:827–832.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Spellberg B,
    2. Bonomo RA
    . 2014. The deadly impact of extreme drug resistance in Acinetobacter baumannii. Crit Care Med42:1289–1291. doi:10.1097/CCM.0000000000000181.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Al-Agamy MH,
    2. Khalaf NG,
    3. Tawfick MM,
    4. Shibl AM,
    5. El Kholy A
    . 2014. Molecular characterization of carbapenem-insensitive Acinetobacter baumannii in Egypt. Int J Infect Dis22:49–54. doi:10.1016/j.ijid.2013.12.004.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Perez F,
    2. Hujer AM,
    3. Hujer KM,
    4. Decker BK,
    5. Rather PN,
    6. Bonomo RA
    . 2007. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother51:3471–3484. doi:10.1128/AAC.01464-06.
    OpenUrlFREE Full Text
  10. 10.↵
    1. Fonseca EL,
    2. Scheidegger E,
    3. Freitas FS,
    4. Cipriano R,
    5. Vicente AC
    . 2013. Carbapenem-resistant Acinetobacter baumannii from Brazil: role of carO alleles expression and blaOXA-23 gene. BMC Microbiol13:245. doi:10.1186/1471-2180-13-245.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Sugawara E,
    2. Nikaido H
    . 2012. OmpA is the principal nonspecific slow porin of Acinetobacter baumannii. J Bacteriol194:4089–4096. doi:10.1128/JB.00435-12.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Smani Y,
    2. Fabrega A,
    3. Roca I,
    4. Sanchez-Encinales V,
    5. Vila J,
    6. Pachon J
    . 2014. Role of OmpA in the multidrug resistance phenotype of Acinetobacter baumannii. Antimicrob Agents Chemother58:1806–1808. doi:10.1128/AAC.02101-13.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Mussi MA,
    2. Relling VM,
    3. Limansky AS,
    4. Viale AM
    . 2007. CarO, an Acinetobacter baumannii outer membrane protein involved in carbapenem resistance, is essential for l-ornithine uptake. FEBS Lett581:5573–5578. doi:10.1016/j.febslet.2007.10.063.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Catel-Ferreira M,
    2. Nehme R,
    3. Molle V,
    4. Aranda J,
    5. Bouffartigues E,
    6. Chevalier S,
    7. Bou G,
    8. Jouenne T,
    9. De E
    . 2012. Deciphering the function of the outer membrane protein OprD homologue of Acinetobacter baumannii. Antimicrob Agents Chemother56:3826–3832. doi:10.1128/AAC.06022-11.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Brown S,
    2. Amyes SG
    . 2005. The sequences of seven class D beta-lactamases isolated from carbapenem-resistant Acinetobacter baumannii from four continents. Clin Microbiol Infect11:326–329. doi:10.1111/j.1469-0691.2005.01096.x.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Girlich D,
    2. Poirel L,
    3. Nordmann P
    . 2010. First isolation of the blaOXA-23 carbapenemase gene from an environmental Acinetobacter baumannii isolate. Antimicrob Agents Chemother54:578–579. doi:10.1128/AAC.00861-09.
    OpenUrlFREE Full Text
  17. 17.↵
    1. Cornaglia G,
    2. Giamarellou H,
    3. Rossolini GM
    . 2011. Metallo-beta-lactamases: a last frontier for beta-lactams?Lancet Infect Dis11:381–393. doi:10.1016/S1473-3099(11)70056-1.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Poirel L,
    2. Nordmann P
    . 2006. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect12:826–836. doi:10.1111/j.1469-0691.2006.01456.x.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    1. Viehman JA,
    2. Nguyen MH,
    3. Doi Y
    . 2014. Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections. Drugs74:1315–1333. doi:10.1007/s40265-014-0267-8.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Levin AS,
    2. Levy CE,
    3. Manrique AE,
    4. Medeiros EA,
    5. Costa SF
    . 2003. Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam. Int J Antimicrob Agents21:58–62. doi:10.1016/S0924-8579(02)00276-5.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    1. Shin JA,
    2. Chang YS,
    3. Kim HJ,
    4. Kim SK,
    5. Chang J,
    6. Ahn CM,
    7. Byun MK
    . 2012. Clinical outcomes of tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii infection. Yonsei Med J53:974–984. doi:10.3349/ymj.2012.53.5.974.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Principe L,
    2. D'Arezzo S,
    3. Capone A,
    4. Petrosillo N,
    5. Visca P
    . 2009. In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii. Ann Clin Microbiol Antimicrob8:18. doi:10.1186/1476-0711-8-18.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. van Duin D,
    2. Kaye KS,
    3. Neuner EA,
    4. Bonomo RA
    . 2013. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis75:115–120. doi:10.1016/j.diagmicrobio.2012.11.009.
    OpenUrlCrossRef
  24. 24.↵
    1. Balkan II,
    2. Batirel A,
    3. Karabay O,
    4. Agalar C,
    5. Akalin S,
    6. Alici O,
    7. Alp E,
    8. Altay FA,
    9. Altin N,
    10. Arslan F,
    11. Aslan T,
    12. Bekiroglu N,
    13. Cesur S,
    14. Celik AD,
    15. Dogan M,
    16. Durdu B,
    17. Duygu F,
    18. Engin A,
    19. Engin DO,
    20. Gonen I,
    21. Guclu E,
    22. Guven T,
    23. Hatipoglu CA,
    24. Hosoglu S,
    25. Karahocagil MK,
    26. Kilic AU,
    27. Ormen B,
    28. Ozdemir D,
    29. Ozer S,
    30. Oztoprak N,
    31. Sezak N,
    32. Turhan V,
    33. Turker N,
    34. Yilmaz H
    . 2015. Comparison of colistin monotherapy and non-colistin combinations in the treatment of multi-drug resistant Acinetobacter spp. bloodstream infections: a multicenter retrospective analysis. Indian J Pharmacol47:95–100. doi:10.4103/0253-7613.150383.
    OpenUrlCrossRef
  25. 25.↵
    1. Bassetti M,
    2. Righi E,
    3. Esposito S,
    4. Petrosillo N,
    5. Nicolini L
    . 2008. Drug treatment for multidrug-resistant Acinetobacter baumannii infections. Future Microbiol3:649–660. doi:10.2217/17460913.3.6.649.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    1. Olaitan AO,
    2. Morand S,
    3. Rolain JM
    . 2014. Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. Front Microbiol5:643. doi:10.3389/fmicb.2014.00643.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Dolejska M,
    2. Villa L,
    3. Poirel L,
    4. Nordmann P,
    5. Carattoli A
    . 2013. Complete sequencing of an IncHI1 plasmid encoding the carbapenemase NDM-1, the ArmA 16S RNA methylase and a resistance-nodulation-cell division/multidrug efflux pump. J Antimicrob Chemother68:34–39. doi:10.1093/jac/dks357.
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    1. Ritchie DJ,
    2. Garavaglia-Wilson A
    . 2014. A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections. Clin Infect Dis59(Suppl 6):S374–S380. doi:10.1093/cid/ciu613.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Cheah SE,
    2. Johnson MD,
    3. Zhu Y,
    4. Tsuji BT,
    5. Forrest A,
    6. Bulitta JB,
    7. Boyce JD,
    8. Nation RL,
    9. Li J
    . 2016. Polymyxin resistance in Acinetobacter baumannii: genetic mutations and transcriptomic changes in response to clinically relevant dosage regimens. Sci Rep6:26233. doi:10.1038/srep26233.
    OpenUrlCrossRef
  30. 30.↵
    1. Lapuebla A,
    2. Abdallah M,
    3. Olafisoye O,
    4. Cortes C,
    5. Urban C,
    6. Landman D,
    7. Quale J
    . 2015. Activity of imipenem with relebactam against Gram-negative pathogens from New York City. Antimicrob Agents Chemother59:5029–5031. doi:10.1128/AAC.00830-15.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Mushtaq S,
    2. Warner M,
    3. Livermore DM
    . 2010. In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters. J Antimicrob Chemother65:2376–2381. doi:10.1093/jac/dkq306.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    1. Curcio D
    . 2011. Activity of a novel combination against multidrug-resistant nonfermenters: ceftazidime plus NXL104. Expert Rev Anti Infect Ther9:173–176. doi:10.1586/eri.10.173.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Papp-Wallace KM,
    2. Bonomo RA
    . 2016. New beta-lactamase inhibitors in the clinic. Infect Dis Clin North Am30:441–464. doi:10.1016/j.idc.2016.02.007.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Livermore DM,
    2. Warner M,
    3. Mushtaq S,
    4. Woodford N
    . 2015. Interactions of OP0595, a novel triple-action diazabicyclooctane, with beta-lactams against OP0595-resistant Enterobacteriaceae mutants. Antimicrob Agents Chemother60:554–560. doi:10.1128/AAC.02184-15.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Morinaka A,
    2. Tsutsumi Y,
    3. Yamada M,
    4. Suzuki K,
    5. Watanabe T,
    6. Abe T,
    7. Furuuchi T,
    8. Inamura S,
    9. Sakamaki Y,
    10. Mitsuhashi N,
    11. Ida T,
    12. Livermore DM
    . 2015. OP0595, a new diazabicyclooctane: mode of action as a serine beta-lactamase inhibitor, antibiotic and beta-lactam ‘enhancer.” J Antimicrob Chemother70:2779–2786. doi:10.1093/jac/dkv166.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Moya B,
    2. Barcelo I,
    3. Udaykar A,
    4. Bhagwat S,
    5. Patel M,
    6. Bou G,
    7. Oliver A
    . 2016. WCK 5222 [cefepime-zidebactam, FEP-ZID]: mechanistic basis behind novel β-lactam–β-lactam enhancer combination against metallo-β-lactamase (MBL)-producing E. coli (EC), K. pneumoniae (KP), P. aeruginosa (PA) and its impact on therapeutically relevant bactericidal exposures assessed through in vitro pharmacodynamic modelling (IVPM) and mouse lung eradication studies, abstr 1982. Abstr IDWeek 2016,New Orleans, LA.
  37. 37.↵
    1. Livermore DM,
    2. Mushtaq S,
    3. Warner M,
    4. Vickers A,
    5. Woodford N
    . 2017. In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria. J Antimicrob Chemother72:1371–1385. doi:10.1093/jac/dkw593.
    OpenUrlCrossRef
  38. 38.↵
    1. Moya B,
    2. Barcelo IM,
    3. Bhagwat S,
    4. Patel M,
    5. Bou G,
    6. Papp-Wallace KM,
    7. Bonomo RA,
    8. Oliver A
    . 2017. WCK 5107 (zidebactam) and WCK 5153 are novel inhibitors of PBP2 showing potent “β-lactam enhancer” activity against Pseudomonas aeruginosa, including multidrug-resistant metallo-β-lactamase-producing high-risk clones. Antimicrob Agents Chemother61:e02529-16. doi:10.1128/AAC.02529-16.
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    1. Penwell WF,
    2. Shapiro AB,
    3. Giacobbe RA,
    4. Gu RF,
    5. Gao N,
    6. Thresher J,
    7. McLaughlin RE,
    8. Huband MD,
    9. DeJonge BL,
    10. Ehmann DE,
    11. Miller AA
    . 2015. Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii. Antimicrob Agents Chemother59:1680–1689. doi:10.1128/AAC.04808-14.
    OpenUrlAbstract/FREE Full Text
  40. 40.↵
    1. Hofer B,
    2. Dantier C,
    3. Gebhardt K,
    4. Desarbre E,
    5. Schmitt-Hoffmann A,
    6. Page MG
    . 2013. Combined effects of the siderophore monosulfactam BAL30072 and carbapenems on multidrug-resistant Gram-negative bacilli. J Antimicrob Chemother68:1120–1129. doi:10.1093/jac/dks527.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Papp-Wallace KM,
    2. Senkfor B,
    3. Gatta J,
    4. Chai W,
    5. Taracila MA,
    6. Shanmugasundaram V,
    7. Han S,
    8. Zaniewski RP,
    9. Lacey BM,
    10. Tomaras AP,
    11. Skalweit MJ,
    12. Harris ME,
    13. Rice LB,
    14. Buynak JD,
    15. Bonomo RA
    . 2012. Early insights into the interactions of different beta-lactam antibiotics and beta-lactamase inhibitors against soluble forms of Acinetobacter baumannii PBP1a and Acinetobacter sp. PBP3. Antimicrob Agents Chemother56:5687–5692. doi:10.1128/AAC.01027-12.
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    1. Dougherty TJ,
    2. Kennedy K,
    3. Kessler RE,
    4. Pucci MJ
    . 1996. Direct quantitation of the number of individual penicillin-binding proteins per cell in Escherichia coli. J Bacteriol178:6110–6115. doi:10.1128/jb.178.21.6110-6115.1996.
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    1. Satta G,
    2. Cornaglia G,
    3. Mazzariol A,
    4. Golini G,
    5. Valisena S,
    6. Fontana R
    . 1995. Target for bacteriostatic and bactericidal activities of beta-lactam antibiotics against Escherichia coli resides in different penicillin-binding proteins. Antimicrob Agents Chemother39:812–818.
    OpenUrlAbstract/FREE Full Text
  44. 44.↵
    1. Takalkar S,
    2. Chavan R,
    3. Patel A,
    4. Umarkar K,
    5. Satav J,
    6. Udaykar A,
    7. Kulkarni A,
    8. Zope V,
    9. Bhagwat S,
    10. Patel M
    . 2016. WCK 5222 [cefepime (FEP)-WCK 5107 (zidebactam, ZID)]: thigh and lung PK/PD studies against higher MIC OXA carbapenemase-expressing A. baumannii (AB), abstr 441. Abstr ASM Microbe 2016. American Society for Microbiology,Washington, DC.
  45. 45.↵
    1. Espinal P,
    2. Macia MD,
    3. Roca I,
    4. Gato E,
    5. Ruiz E,
    6. Fernandez-Cuenca F,
    7. Oliver A,
    8. Rodriguez-Bano J,
    9. Bou G,
    10. Tomas M,
    11. Vila J
    . 2013. First report of an OXA-23 carbapenemase-producing Acinetobacter baumannii clinical isolate related to Tn2006 in Spain. Antimicrob Agents Chemother57:589–591. doi:10.1128/AAC.01157-12.
    OpenUrlAbstract/FREE Full Text
  46. 46.↵
    1. Hujer KM,
    2. Hujer AM,
    3. Hulten EA,
    4. Bajaksouzian S,
    5. Adams JM,
    6. Donskey CJ,
    7. Ecker DJ,
    8. Massire C,
    9. Eshoo MW,
    10. Sampath R,
    11. Thomson JM,
    12. Rather PN,
    13. Craft DW,
    14. Fishbain JT,
    15. Ewell AJ,
    16. Jacobs MR,
    17. Paterson DL,
    18. Bonomo RA
    . 2006. Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. Antimicrob Agents Chemother50:4114–4123. doi:10.1128/AAC.00778-06.
    OpenUrlAbstract/FREE Full Text
  47. 47.↵
    1. Moya B,
    2. Beceiro A,
    3. Cabot G,
    4. Juan C,
    5. Zamorano L,
    6. Alberti S,
    7. Oliver A
    . 2012. Pan-beta-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities. Antimicrob Agents Chemother56:4771–4778. doi:10.1128/AAC.00680-12.
    OpenUrlAbstract/FREE Full Text
  48. 48.↵
    1. Zhao G,
    2. Meier TI,
    3. Kahl SD,
    4. Gee KR,
    5. Blaszczak LC
    . 1999. Bocillin FL, a sensitive and commercially available reagent for detection of penicillin-binding proteins. Antimicrob Agents Chemother43:1124–1128.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Download PDF
Citation Tools
Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates
Bartolome Moya, Isabel M. Barcelo, Sachin Bhagwat, Mahesh Patel, German Bou, Krisztina M. Papp-Wallace, Robert A. Bonomo, Antonio Oliver
Antimicrobial Agents and Chemotherapy Oct 2017, 61 (11) e01238-17; DOI: 10.1128/AAC.01238-17

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates
Bartolome Moya, Isabel M. Barcelo, Sachin Bhagwat, Mahesh Patel, German Bou, Krisztina M. Papp-Wallace, Robert A. Bonomo, Antonio Oliver
Antimicrobial Agents and Chemotherapy Oct 2017, 61 (11) e01238-17; DOI: 10.1128/AAC.01238-17
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • RESULTS AND DISCUSSION
    • MATERIALS AND METHODS
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Acinetobacter baumannii
Anti-Bacterial Agents
Aza Compounds
Azabicyclo Compounds
Cyclooctanes
Hydrazines
Piperidines
MDR A. baumannii
PBP IC50
WCK 5153
β-lactam enhancer
zidebactam

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596